Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-07

Clinical Trial Update: Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone [Phase 3]

View source ↗

Summary

A Phase 3 pivotal trial assessing lubiprostone for opioid-induced bowel dysfunction has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUBIPROSTONE (lubiprostone)

Snippet

Sponsor: Sucampo Pharma Americas, LLC | Conditions: Opioid-Induced Bowel Dysfunction | Phase 3 | Status: COMPLETED | Results posted: 2015-12-07